Benitec Biopharma Limited (BNTC) closed the last trading session at $15.49, gaining 14.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $25.71 indicates a 66% upside potential.The average comprises seven short-term price targets ranging from a low of $17 to a high of $35, with a standard deviation of $6.70. While the lowest estimate indicates an increase of 9.8% from the current ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Benitec Biopharma Limited (BNTC) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Benitec Biopharma Limited is a member of our Medical group, which includes 999 different companies and currently sits at #4 in the Zacks Sector Rank. The Zacks Sector Rank includes 1 ...

Group 1 - The core viewpoint is that Benitec Biopharma Limited (BNTC) has significant upside potential, with a mean price target of $25.71 indicating an 83.9% increase from its current price of $13.98 [1] - The mean estimate consists of seven short-term price targets with a standard deviation of $6.70, suggesting variability in analyst predictions; the lowest estimate is $17 (21.6% increase), while the highest is $35 (150.4% increase) [2] - Analysts show strong agreement on BNTC's ability to report better earnings than previously predicted, which supports the expectation of stock upside [4][11] Group 2 - The Zacks Consensus Estimate for BNTC has increased by 15.6% due to three upward revisions in earnings estimates over the last 30 days, with no negative revisions [12] - BNTC holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [13] - While price targets may not be entirely reliable, the direction they imply appears to be a good guide for potential price movement [13]

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Benitec Biopharma Limited (BNTC) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Benitec Biopharma Limited is a member of our Medical group, which inclu ...

Financial Performance - Total expenses for Q3 2025 were $10.2 million, up from $4.1 million in Q3 2024, representing a 148.8% increase[4] - The net loss attributable to shareholders for Q3 2025 was $9.4 million, or $0.24 per share, compared to a net loss of $4.3 million, or $0.23 per share in Q3 2024[5] - The company reported a total comprehensive loss of $9.4 million for Q3 2025, compared to a comprehensive loss of $4.2 million in Q3 2024[9] - Total operating expenses for the nine months ended March 31, 2025, were $24.6 million, compared to $16.9 million for the same period in 2024, indicating a 45.5% increase[9] Research and Development - Research and development expenses for the quarter were $6.0 million, compared to $2.6 million in the same quarter last year, marking a 130.8% increase[4] - The company is focused on the continued development of BB-301 for the treatment of dysphagia in OPMD patients[3] - The company plans to enroll additional subjects at a higher dose of BB-301 later this year, following the successful treatment of the sixth subject in Cohort 1[3] Assets and Cash Position - As of March 31, 2025, the company had $103.6 million in cash and cash equivalents, an increase from $50.9 million as of June 30, 2024[7] - The total assets as of March 31, 2025, were $105.2 million, compared to $52.2 million as of June 30, 2024, reflecting a 101.5% increase[7] Earnings Per Share - The basic earnings per share calculation has been revised to include pre-funded warrants in the weighted number of shares outstanding for the current and comparative periods[5]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39267 BENITEC BIOPHARMA INC. (Exact name of registrant as specified in its charter) Delaware 84-462-0206 (State or other jurisdicti ...

Core Viewpoint - The article emphasizes the importance of identifying sustainable trends in stock prices for short-term investing, highlighting that while price movements can be profitable, they can also reverse quickly, leading to potential losses [1][2]. Group 1: Stock Performance - Benitec Biopharma Limited (BNTC) has shown a solid price increase of 43.2% over the past 12 weeks, indicating strong investor interest [4]. - The stock has also increased by 22.2% in the last four weeks, suggesting that the upward trend is still intact [5]. - BNTC is currently trading at 83.4% of its 52-week high-low range, indicating a potential breakout [5]. Group 2: Fundamental Strength - BNTC holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises [6]. - The stock has an Average Broker Recommendation of 1 (Strong Buy), reflecting high optimism from the brokerage community regarding its near-term price performance [7]. Group 3: Investment Strategy - The article suggests using the "Recent Price Strength" screen to identify stocks like BNTC that are on an upward trend supported by strong fundamentals [3][8]. - It also mentions that there are over 45 Zacks Premium Screens available for investors to find winning stock picks based on their personal investing styles [8].

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Benitec Biopharma Limited (BNTC) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.Benitec Biopharma Limited is a member of the Medical sector. This group includes 1001 individual stocks and currently holds a Zacks Sector Rank of #4. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average ...

Core Viewpoint - Benitec Biopharma Limited (BNTC) shows significant upside potential with a mean price target of $25.71, indicating an 85% increase from the current price of $13.90 [1] Price Targets - The average of seven short-term price targets ranges from a low of $17 to a high of $35, with a standard deviation of $6.70, suggesting variability in analyst estimates [2] - The lowest estimate indicates a 22.3% increase, while the highest suggests a 151.8% upside [2] Analyst Consensus - Strong agreement among analysts regarding BNTC's ability to report better earnings than previously predicted supports the potential for stock upside [4] - The Zacks Consensus Estimate for the current year has increased by 0.7% over the past month, with one estimate rising and no negative revisions [12] Zacks Rank - BNTC holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Earnings Estimate Revisions - Analysts' optimism regarding BNTC's earnings prospects, reflected in the upward revisions of EPS estimates, correlates strongly with near-term stock price movements [11]

Benitec Biopharma Limited (BNTC) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Individual investo ...